Electromed earnings release, May 12, 2026

Electromed, Inc. (ELMD) · Form 8-K, Item 2.02 · Filed · SEC filing

Electromed, Inc. Announces Record Financial Performance in Fiscal 2026

Third

Quarter

18% Revenue growth and strong operating leverage exceeds consensus expectations for the third quarter of fiscal 2026

NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three and nine months ended March 31, 2026

(“

Q3

FY

2026”).

Q3

FY

2026

Company Highlights

“I'm happy to report that Electromed has delivered its 14th consecutive quarter of year-over-year revenue and profit growth. Electromed's unique business model created to address the underserved airway clearance market is achieving the desired results we had expected,” said Jim Cunniff, President and Chief Executive Officer. “We continue to make investments in our sales and fulfillment teams to drive greater prescription volumes and faster delivery of our SmartVest therapy to more patients. With 86% of covered lives in the United States now under contract and our manufacturing optimization complete, we're well-positioned to capture the opportunity in the underserved bronchiectasis market. As we look ahead, our strong operational foundation, strategic investments, and continued focus on education and awareness give us confidence in sustaining our trajectory of profitable growth."

Q3

FY

2026

Results

All amounts below are for the three months ended

March 31, 2026, and compare to the three months ended

March 31, 2025

(“

Q3

FY

2025”).

Net revenues grew

18.4% to $

18.6 million, from $

15.7 million.

Revenue in our direct homecare business increased by

18.6% to $

16.7 million, from $

14.1 million. The increase in revenue was primarily due to an increase in direct sales representatives, increased sales representative productivity, and higher net revenues per sales representative. Throughout

Q3 FY 2026, we averaged⁵⁷ homecare direct field sales representatives. The annualized homecare revenue per weighted average direct sales representative in

Q3

FY

2026 was $1,168,000, exceeding Electromed’s target range for the year of $1,000,000 to $1,100,000.

Non-homecare revenue was $

1.8 million. Hospital revenue grew

42.5%, totaling $

1.0 million. Homecare distributor revenue was $

0.7 million, an increase of

2.7%. Other revenue of $

0.1 million declined

40.7%.

Gross profit increased year-over-year to $

14.6 million or

78.8% of net revenues from $

12.2 million or

78.0% of net revenues. The increases in gross profit and gross margin were primarily a result of increased overall revenue and higher net revenues per device.

Selling, general and administrative (“SG&A”) expenses were $

10.5 million, representing an increase of $

0.7 million or

7.2%. The increase in the current period was primarily due to the increased salaries and incentive compensation related to the higher average sales representative headcount and higher overall compensation costs.

Operating income was $

3.8 million or

20.3% of net revenues, compared to $

2.1 million, or

13.6% of net revenues. The

76.0% increase in operating income was primarily due to the increases in revenue and gross profit.

Net income increased by

58.8% to $

3.0 million, or $

0.35 per diluted share, compared to $

1.9 million, or $

0.21 per diluted share.

As of

March 31, 2026, Electromed had $

17.0 million in cash, $

28.3 million in accounts receivable and no debt, achieving a working capital of $

40.0 million and total shareholders’ equity of $

49.2 million. The cash balance reflects an increase of $

1.7 million for the nine months ended March 31, 2026, compared to a decrease in cash of $

0.8 million in the nine months ended March 31, 2025. The increase in cash for the nine months ended March 31, 2026, was driven primarily by positive operating cash flow of $6.7 million, partially offset by share repurchases of $

3.9 million of Electromed common stock.

Conference Call and Webcast Information

The conference call with members of Electromed management will be held at 5:00 p.m. Eastern Time on Tuesday, May 12, 2026.

Interested parties may participate in the call by dialing (877) 407-3982 (Domestic) or (201) 493-6780 (International).

The live conference call webcast will be accessible in the Investor Relations section of Electromed’s website and directly via the following link: https://viavid.webcasts.com/starthere.jsp?ei=1759896&tp_key=ae965d6622

For those who cannot listen to the live broadcast, a replay will be available by dialing (844) 512-2921 (Domestic) or (412) 317-6671 (International) and referencing the Access ID 13760099. Additionally, an online replay of the webcast will be available for one year in the Investor Relations section of Electromed’s web site at: https://investors.smartvest.com/events-and-presentations/default.aspx

About Electromed, Inc.

Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.

Financial statements

Income Statement

Three Months Ended — Condensed Statements of Operations (Unaudited)

Three Months Ended – March 31, – 2026Three Months Ended – March 31, – 2025Nine Months Ended – March 31, – 2026Nine Months Ended – March 31, – 2025
Net revenues18,575,00015,684,00054,359,00046,607,000
Cost of revenues3,932,0003,455,00011,700,00010,260,000
Gross profit14,643,00012,229,00042,659,00036,347,000
Operating expensesSelling, general and administrative10,516,0009,812,00031,617,00029,033,000
Operating expensesResearch and development361,000277,000986,000694,000
Operating expensesTotal operating expenses10,877,00010,089,00032,603,00029,727,000
Operating expensesOperating income3,766,0002,140,00010,056,0006,620,000
Operating expensesInterest income, net100,000142,000343,000489,000
Operating expensesNet income before income taxes3,866,0002,282,00010,399,0007,109,000
Operating expensesIncome tax expense863,000391,0002,499,0001,776,000
Operating expensesNet income3,003,0001,891,0007,900,0005,333,000
Income per share:Basic0.370.220.960.63
Income per share:Diluted0.350.210.910.59
Weighted-average common shares outstanding:Basic8,211,2208,495,0058,268,6058,493,715
Weighted-average common shares outstanding:Diluted8,647,7948,967,8388,673,3458,980,218

Balance Sheet

March 31, 2026 — Condensed Balance Sheets

March 31, 2026 – (Unaudited)June 30, 2025
Current AssetsCash and cash equivalents16,985,00015,287,000
Current AssetsAccounts receivable (net of allowances for credit losses of $45,000)28,251,00024,660,000
Current AssetsContract assets1,086,0001,036,000
Current AssetsInventories3,295,0003,299,000
Current AssetsIncome tax receivable15,000408,000
Current AssetsPrepaid expenses and other current assets596,000392,000
Current AssetsTotal current assets50,228,00045,082,000
Current AssetsProperty and equipment, net5,209,0004,714,000
Current AssetsFinite-life intangible assets, net354,000371,000
Current AssetsOther assets1,221,0001,173,000
Current AssetsDeferred income taxes2,462,0002,462,000
Current AssetsTotal assets59,474,00053,802,000
Current LiabilitiesAccounts payable2,595,0002,667,000
Current LiabilitiesAccrued compensation4,530,0005,079,000
Current LiabilitiesWarranty reserve1,784,0001,645,000
Current LiabilitiesOther accrued liabilities1,317,0001,077,000
Current LiabilitiesTotal current liabilities10,226,00010,468,000
Current LiabilitiesOther long-term liabilities81,000125,000
Current LiabilitiesTotal liabilities10,307,00010,593,000
Shareholders' EquityCommon stock, $0.01 par value per share, 13,000,000 shares authorized; 8,279,845 and 8,349,176 shares issued and outstanding, as of March 31, 2026, and June 30, 2025, respectively83,00083,000
Shareholders' EquityAdditional paid-in capital23,949,00021,941,000
Shareholders' EquityRetained earnings25,135,00021,185,000
Shareholders' EquityTotal shareholders' equity49,167,00043,209,000
Shareholders' EquityTotal liabilities and shareholders' equity59,474,00053,802,000

Cash Flow

Nine Months Ended March 31, — Condensed Statements of Cash Flows (Unaudited)

Nine Months Ended March 31, – 2026Nine Months Ended March 31, – 2025
Cash Flows From Operating ActivitiesNet income7,900,0005,333,000
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation642,000663,000
Adjustments to reconcile net income to net cash provided by operating activities:Amortization162,000112,000
Adjustments to reconcile net income to net cash provided by operating activities:Share-based compensation expense1,960,0002,409,000
Changes in operating assets and liabilities:Accounts receivable-3,591,000-109,000
Changes in operating assets and liabilities:Contract assets-50,000-405,000
Changes in operating assets and liabilities:Inventories-123,000564,000
Changes in operating assets and liabilities:Prepaid expenses and other assets-364,000-779,000
Changes in operating assets and liabilities:Income tax receivable, net393,000-1,209,000
Changes in operating assets and liabilities:Accounts payable and accrued liabilities291,000877,000
Changes in operating assets and liabilities:Accrued compensation-549,00078,000
Changes in operating assets and liabilities:Net cash provided by operating activities6,671,0007,534,000
Cash Flows From Investing ActivitiesExpenditures for property and equipment-1,033,000-117,000
Cash Flows From Investing ActivitiesExpenditures for finite-life intangible assets-44,000-32,000
Cash Flows From Investing ActivitiesNet cash used for investing activities-1,077,000-149,000
Cash Flows From Financing ActivitiesIssuance of common stock upon exercise of options268,000381,000
Cash Flows From Financing ActivitiesTaxes paid on net share settlement of stock awards-246,000-2,278,000
Cash Flows From Financing ActivitiesRepurchase of common stock-3,918,000-6,331,000
Cash Flows From Financing ActivitiesNet cash used for financing activities-3,896,000-8,228,000
Cash Flows From Financing ActivitiesNet increase (decrease) in cash1,698,000-843,000
Cash and cash equivalentsBeginning of period15,287,00016,080,000
Cash and cash equivalentsEnd of period16,985,00015,237,000
Full release

Cautionary Statements... (truncated)ssociated with such statements. Examples of risks and uncertainties for Electromed include, but are not limited to, our ability to obtain reimbursement from Medicare, Medicaid, or private insurance payers for our products; component or raw material shortages, changes to lead times or significant price increases and changes to trade regulations (including, but not limited to, changes to tariffs); adverse changes to state and federal health care regulations; our ability to maintain regulatory compliance and to gain future regulatory approvals and clearances; entry of new competitors including new drug or pharmaceutical discoveries; adverse economic and business conditions or intense competition; wage and component price inflation; technical problems with our research and products; the risks associated with cyberattacks, data breaches, computer viruses and other similar security threats; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the hospital or homecare distributor channels; adverse international health care regulation impacting current international business; our ability to renew our line of credit or obtain additional credit as necessary; and our ability to protect and expand our intellectual property portfolio, as well as other factors we may describe from time to time in Electromed’s reports filed with the Securities and Exchange Commission (including Electromed’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.

Brad Nagel, Chief Financial Officer

(952) 758-9299 investorrelations@electromed.com

Mike Cavanaugh, Investor Relations

ICR Healthcare

(617) 877-9641 mike.cavanaugh@icrhealthcare.com

Source: Electromed, Inc.

Electromed, Inc.

Condensed Balance Sheets

Electromed, Inc.

Condensed Statements of Operations (Unaudited)

Electromed, Inc.

Condensed Statements of Cash Flows (Unaudited)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Electromed earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.